Page last updated: 2024-10-28

hydroxyurea and Acute Coronary Syndrome

hydroxyurea has been researched along with Acute Coronary Syndrome in 4 studies

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gaztanaga, J	1
Farkouh, M	1
Rudd, JH	1
Brotz, TM	2
Rosenbaum, D	1
Mani, V	1
Kerwin, TC	1
Taub, R	2
Tardif, JC	3
Tawakol, A	1
Fayad, ZA	1
Matsumoto, S	1
Ibrahim, R	2
Grégoire, JC	2
L'Allier, PL	2
Pressacco, J	2
Budoff, MJ	1
Kumagai, N	1
Mitsutake, R	1
Miura, S	1
Kawamura, A	1
Takamiya, Y	1
Nishikawa, H	1
Uehara, Y	1
Saku, K	1
Nozza, A	1
Cossette, M	1
Kouz, S	1
Lavoie, MA	1
Paquin, J	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00552188]	Phase 2	52 participants (Actual)	Interventional	2007-10-31	Completed
Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00358826]	Phase 2	191 participants (Actual)	Interventional	2006-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Plaque Imaging After 24 Weeks

To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the target (plaque) to background (blood) ratio (TBR) from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18fluorodeoxy glucose (FDG) uptake measured with PET in patients with acute coronary syndrome and vascular inflammation after 24 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 24 Weeks

Intervention	TBR (Least Squares Mean)
VIA-2291	-0.01
Placebo	-0.06

Change From Baseline in Plaque Imaging After 6 Weeks

To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the TBR from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18FDG uptake measured with PET in patients after 6 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 6 Weeks

Intervention	TBR (Least Squares Mean)
VIA-2291	0.01
Placebo	-0.07

Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - Core Study

(NCT00358826)
Timeframe: Baseline and 12 weeks

Intervention	mg/L (Median)
VIA-2291 25 mg	-0.2
VIA-2291 50 mg	-0.1
VIA-2291 100 mg	-0.3
Placebo	-0.2

Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - MDCT Substudy

(NCT00358826)
Timeframe: Baseline and 24 weeks

Intervention	mg/L (Median)
VIA-2291 25 mg MDCT Substudy	-0.4
VIA-2291 50 mg MDCT Substudy	-0.2
VIA-2291 100 mg MDCT Substudy	-0.4
Placebo MDCT Substudy	0.0

Change From Baseline in Leukotriene E4 (LTE4)

Urinary LTE4 is expressed in pg per mg Creatinine (pg/mg Cr) to normalize for renal excretion rate (NCT00358826)
Timeframe: Baseline and 12 weeks

Intervention	pg/mg Cr (Least Squares Mean)
VIA-2291 25 mg	-26.8
VIA-2291 50 mg	-38.6
VIA-2291 100 mg	-56.5
Placebo	8.4

Change From Baseline in Mean Plaque Density

Plaque density is expressed in Hounsfield Units (HU) (NCT00358826)
Timeframe: Baseline and 24 weeks

Intervention	HU (Least Squares Mean)
VIA-2291 25 mg	19.11
VIA-2291 50 mg	7.39
VIA-2291 100 mg	12.22
Placebo	12.42

Change From Baseline in Noncalcified Plaque Volume

(NCT00358826)
Timeframe: Baseline and 24 weeks

Intervention	mm^3 (Least Squares Mean)
VIA-2291 25 mg MDCT Substudy	-1.55
VIA-2291 50 mg MDCT Substudy	-5.6
VIA-2291 100 mg MDCT Substudy	0.15
Placebo MDCT Substudy	2.83

Change From Baseline in Percent Stenosis

(NCT00358826)
Timeframe: Baseline and 24 weeks

Intervention	Percentage (Least Squares Mean)
VIA-2291 25 mg	-0.11
VIA-2291 50 mg	11.45
VIA-2291 100 mg	2.36
Placebo	1.19

Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood

(NCT00358826)
Timeframe: Baseline and 12 weeks

Intervention	pg/mL (Least Squares Mean)
VIA-2291 25 mg	-88126
VIA-2291 50 mg	-95703
VIA-2291 100 mg	-122668
Placebo	-20843

Trials

3 trials available for hydroxyurea and Acute Coronary Syndrome

Article	Year
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis, 2015, Volume: 240, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aortitis; Aortography; Canada; Carotid Artery Diseases; Double-Blind	2015
Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. Clinical cardiology, 2017, Volume: 40, Issue:4 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Computed Tomography Angiography; Coronary V	2017
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circulation. Cardiovascular imaging, 2010, Volume: 3, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Analysis of Variance; Arachidonate 5-Lipoxy	2010

Other Studies

1 other study available for hydroxyurea and Acute Coronary Syndrome

Article	Year
Acute coronary syndrome associated with essential thrombocythemia. Journal of cardiology, 2009, Volume: 54, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Therapy, Combinat	2009